Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Advaxis

NASDAQ ADXS
$0.22 0.0000 0.0000%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 16 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

32.04M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
7.82M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
2.30
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
145.64M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-67.02 %

Upcoming events Advaxis

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Advaxis

Stock analysis Advaxis

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-1.70 28.84
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
1.06 4.35
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-0.40 10.00
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
1.25 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-42.64 7.67

Price change Advaxis per year

0.27$ 1.57$
Min Max

Summary analysis Advaxis

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Advaxis

Revenue and net income Advaxis

All parameters

Stock news Advaxis

All news
19 October 2022 в 18:50

Ayala Pharmaceuticals Shares Slide to New Lows on Advaxis Tie-Up >AYLA

19 October 2022 в 18:50

Ayala Pharmaceuticals Shares Slide to New Lows on Advaxis Tie-Up >AYLA

19 October 2022 в 14:01

Ayala Pharmaceuticals, Advaxis to Combine in Stock Deal >AYLA ADXS

19 October 2022 в 13:55

Ayala Pharmaceuticals, Advaxis to Combine in Stock Deal >AYLA ADXS

17 December 2021 в 17:05

Advaxis Shares Edge Up After Reverse Stock Split Not Approved

17 December 2021 в 17:00

Advaxis Shares Edge Up After Reverse Stock Split Not Approved

About company Advaxis

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Address:
9 Deer Park Drive, Monmouth Junction, NJ, United States, 08852
Company name: Advaxis
Issuer ticker: ADXS
ISIN: US0076243072
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2005-07-28
Sector: Healthcare
Industry: Biotechnology
Site: https://www.advaxis.com

On which stock exchange are Advaxis (ADXS) stocks traded?

Advaxis (ADXS) stocks are traded on NASDAQ.

What is the ticker of Advaxis stocks (ADXS)?

The stock ticker of Advaxis’s stocks or in other words, the code is ADXS. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Advaxis (ADXS) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Advaxis (ADXS) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Advaxis (ADXS) stocks traded?

Advaxis (ADXS) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Advaxis (ADXS) stocks today?

The current price of Advaxis stocks on 20.05.2024 is 0.22 dollars. per share.

What is the dynamics of Advaxis (ADXS) stocks from the beginning of the year?

Advaxis (ADXS) quotes have increased by -65.08% from the beginning of the year up to 0.22 dollars. per 1 stocks.

How much did Advaxis (ADXS) stocks increase in мае 2024?

This month Advaxis (ADXS) quotes have increased by -65.79% to 0.22 dollars. per share.

How much are Advaxis (ADXS) stocks worth?

Today, on October, 20.05.2024 Advaxis’s (ADXS) stocks cost 0.22 dollars..

What is the market capitalization of Advaxis (ADXS)?

Capitalization is the market value of Advaxis (ADXS) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 20.05.2024, the market capitalization of Advaxis (ADXS) is estimated at about 32040461 dollars.